Glucose‐6‐phosphate dehydrogenase deficiency in dermatology

Update on topical antibiotics in dermatology

“…In a separate study of patients with G6PD deficiency, no clinical signs or symptoms of hemolytic anemia were detected. This was expected given that the plasma levels with the gel formulation have been shown to be extremely low and that anemia is a dose-dependent risk (13,14).…”

“…More recently, "sulfa allergy" has become inclusive of any drug containing a sulfur dioxide and a nitrogen moiety (SO2NH2), a commonly found structure in many disparate molecules, including diuretics and nonsteroidal anti-inflammatory agents. It is a misconception that "sulfa allergy" to a sulfa antibiotic necessarily indicates allergies to sulfa nonantibiotics or drugs containing arylamines or sulfate groups (13).…”

A toxic epidermal necrolysis-like presentation of linear IgA bullous dermatosis treated with dapsone

“…Screening is more relevant in patients considered to be at higher risk for the enzyme deficiency, particularly males of African, Asian, or Mediterranean descent [6,39]. The qualitative fluorescent spot test is useful for rapid population screening, whereas a quantitative spectrophotometric analysis provides definitive diagnosis [40,41].…”

“…Most patients on dapsone, regardless of G6PD status, have some degree of hemolysis that does not produce clinically significant anemia [38]. Even in G6PD-deficient individuals, dapsone-induced hemolysis is usually a mild self-limiting process and a dose of 100 mg daily may be safely administered [40]. Hemolysis may be detected clinically within 24-72 hours of drug administration, characteristically presenting as hemoglobinuria, whereas anemia worsens until days 7-8 [41].…”

Hematologic Safety of Dapsone Gel, 5%, for Topical Treatment of Acne Vulgaris

“…However, clinically relevant hemolysis is generally not apparent with oral dapsone doses of 50 mg or less in G6PD-deficient subjects compared with 100 mg or less in normal subjects. [9][10][11]…”